Skip to main content
Journal of Clinical Oncology logoLink to Journal of Clinical Oncology
. 2019 Feb 1;37(4):354. doi: 10.1200/JCO.18.02211

Errata

PMCID: PMC6827954  PMID: 30695658

The May 20, 2015, article by Baselga et al entitled “Reply to A. Avan et al” (J Clin Oncol 33:1712, 2015) was published with errors in the AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST section.

Dr Baselga’s COIs were given as:

José Baselga

Honoraria: Roche

They should have read as:

José Baselga

Leadership: Infinity Pharmaceuticals, Aura Biosciences

Stock or Other Ownership: PMV Pharma, Juno Therapeutics, Infinity Pharmaceuticals, GRAIL, Aura Biomedical, Apogen, Seragon, Aragon, Verastem

Honoraria: PMV Pharma, Juno Therapeutics, Infinity Pharmaceuticals, Seragon

Consulting or Advisory Role: Eli Lilly, Novartis, GRAIL, AstraZeneca

Research Funding: Roche/Genentech

Travel, Accommodations, Expenses: Roche/Genentech

This has been corrected as of January 11, 2019. The author apologizes for the errors.


Articles from Journal of Clinical Oncology are provided here courtesy of American Society of Clinical Oncology

RESOURCES